IP Library Granted Patent US 8,871,458
Granted Patent B2
US 8,871,458 · App. 12/644,209 · Granted Oct 28, 2014

Methods for detecting risk of fatal prostate cancer using serum calcium

Inventors: Gary G. Schwartz (Winston-Salem, NC); Halcyon G. Skinner (Middleton, WI)
Assignee: Wake Forest University Health Sciences
G01N33/84G01N33/574G01N33/57434G01J3/42G01J3/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,458
App. No.
12/644,209
Granted
Oct 28, 2014
Kind
B2
Abstract

A method of screening for increased risk of fatal prostate cancer in a subject comprises providing a blood sample collected from the subject, and then detecting the presence or absence of an increased level of serum calcium in the sample. An increased level of serum calcium indicates the subject is at increased risk of fatal prostate cancer.

Claims (10)

1. A method of screening for increased risk of developing fatal prostate cancer in a human male subject in need thereof, comprising: providing a blood sample collected from said subject; and detecting the presence or absence of an increased level of serum calcium in said sample, an increased level of serum calcium indicating said subject is at increased risk of fatal prostate cancer; wherein said serum calcium is total serum calcium and said increased level is greater than 2.3 mmol/L, and said detecting step is carried out by absorption spectrometry.

2. The method of claim 1 , wherein said blood sample comprises whole blood, blood plasma, or blood serum.

3. The method of claim 1 , wherein said providing step comprises collecting a blood sample from said subject.

4. The method of claim 1 , wherein said providing step comprises at least partially purifying said blood sample.

5. The method of claim 1 , wherein said detecting step is a quantitative detecting step.

6. A method of screening for increased risk of developing fatal prostate cancer in a human male subject in need thereof, comprising: providing a blood sample collected from said subject; and detecting the presence or absence of an increased level of serum calcium in said sample, an increased level of serum calcium indicating said subject is at increased risk of fatal prostate cancer; wherein said serum calcium is total serum calcium and said increased level is greater than 2.3 mmol/L, and said detecting step is carried out by: atomizing said sample in an atomic absorption spectrophotometer to provide an atomized sample; then illuminating said atomized sample with light in said atomic absorption spectrophotometer; then detecting light from said atomized sample with a detector; and then determining the amount of total serum calcium in said sample from said detected light by atomic absorption spectrophotometry.

7. The method of claim 6 , wherein said blood sample comprises whole blood, blood plasma, or blood serum.

8. The method of claim 6 , wherein said providing step comprises collecting a blood sample from said subject.

9. The method of claim 6 , wherein said providing step comprises at least partially purifying said blood sample.

10. The method of claim 6 , wherein said detecting step is a quantitative detecting step.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 10, 2014
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034196/0283 →
Continuity (2)
Provisional Application 61141068 · Dec 29, 2008
Related Publication 20100167325A1 · Jul 1, 2010